Press Release – Empyrean Medical Systems

Osceola County Commission Approves Negotiations with Medical Device Company to Establish Presence at NeoCity

sageadmin — Tue, 17 Dec 2024 14:49:00 +0000

Osceola County, Florida – The Osceola County Board of County Commissioners has approved a Memorandum of Understanding (MOU) with Concept Companies and Empyrean Medical Systems, Inc., a global medical device technology company, marking another significant step in developing NeoCity as a premier technological innovation district.

Under Monday’s MOU, Empyrean would consider leasing space at NeoCity in 2025, focusing on advanced engineering and precision parts fabrication for radiation oncology devices, medical imaging, and superconducting technologies for its particle accelerators. The strategic partnership could represent the first phase of a comprehensive plan to establish a 50,000- to 100,000-square foot facility by early 2028, which will consolidate Empyrean’s advanced superconducting and magnetics research and development, manufacturing, and administrative operations.

“The MOU with Empyrean’s exemplifies the type of innovative, technology-driven companies we are attracting to NeoCity,” said Viviana Janer, Chair of the Osceola County Commission. “By leveraging our semiconductor ecosystem and advanced technical infrastructure, we’re creating a magnet for cutting-edge technological enterprises that drive economic diversification and high-value job creation.”

The company would create at least 60 high-skilled positions with an average annual salary of $80,000 by 2033, further strengthening the region’s advanced technology workforce.

Empyrean was founded to fundamentally disrupt and replace current devices and technologies employed to treat cancer patients worldwide.

Kal Fishman, President and CEO of Empyrean, said, “NeoCity’s sophisticated technological ecosystem provides us with an unparalleled environment for innovation. NeoCity allows us to tap into a rich network of technological resources and talent. It uniquely enables our research and development work, precision fabrication, and manufacturing of our state-of-the-art products and components. We are proud to consider establishing our most advanced facility at NeoCity in our home state of Florida and create new high-skilled job opportunities in Osceola County in full collaboration with Magnetics Corporation, our strategic partner in this project.”

Magnetics Corporation (MagCorp) is a key connecting partner, bringing Empyrean and the County together to create continued progress towards a future that will generationally advance critical commercial technologies in energy and health.

Concept Companies is the real estate developer for the project and would complete the purpose-built facility for the company at NeoCity that could be sized between 50,000 and 100,000 square feet.

“Concept specializes in science, technology, and healthcare real estate development projects,” said Seth Lane, Executive Vice President of Real Estate for Concept Companies. “Working with Empyrean with the strong support of Osceola County and the NeoCity team will yield a tremendous project that is transformational for our community.”

With the MOU approval, the County, Concept and Empyrean have 120 days to finalize a comprehensive development agreement, continuing Osceola County’s strategic vision of creating a dynamic, technology-driven economic landscape.

The investment builds upon NeoCity’s growing momentum in technological development, including:

Creation of the Central Florida Semiconductor Innovation Engine through a National Science Foundation award
Critical funding from the Department of Defense and U.S. Economic Development Administration
Establishment of a semiconductor accelerator program by Plug and Play
Partnerships with leading technology institutions like SkyWater Technology, imec USA, and multiple universities

By attracting innovative companies like Empyrean and building a robust technology ecosystem with partners such as Concept and MagCorp, Osceola County is positioning itself at the forefront of high-tech innovation and inclusive economic growth.

About Empyrean

Using highly specialized magnetics, photonics, novel particle accelerators, and advanced materials science, Empyrean Medical Systems, Inc.’s products integrate the latest in quantum physics, high-temperature superconductors (HTS), synthetic diamonds, molecular biology, and machine learning to offer first-in-class accuracy, efficacy, and safety in cancer treatment.

About Concept

Since 2004, Concept Companies have created environments that enhance, empower, and inspire. Concept Companies is a nationwide, full-service real estate company, headquartered in Gainesville. It has built a team of trusted experts across multiple sectors, including Mixed-use Masterplan Developments, Science and Technology, Industrial, and Office. Concept Companies has developed more than 300 projects totaling more than 10 million square feet across various sectors in the United States.

About Magnetics Corporation

MagCorp is on a mission to usher in the industrial era of superconductivity through its ongoing efforts in private-sector joint technology development, public-private partnered economic development and corporate growth solutions. MagCorp is leading the creation of the world’s first commercial HTS ecosystem and anchoring it in the State of Florida to solve some of the most pressing grand challenges to humanity.

About Osceola County and NeoCity

Osceola County is one of the fastest growing counties in the nation. It is a dynamic and innovative community focused on a vision to be the center of research and manufacturing innovation of a regional economy and in doing so, it aims to enhance the quality of life for its residents using responsible resource management, innovative public services, and community engagement. Following the impacts of the COVID-19 pandemic, when unemployment hit 30 percent (the highest in the state), Osceola County decided to make a long-term investment to create a 500-acre technology district known as NeoCity to diversify its economy. Working with the National Science Foundation, the Central Florida Semiconductor Innovation Engine seeks to be a global leader in the advanced and specialty packaging of semiconductors based in Florida.

###

La Comisión del Condado de Osceola Aprueba las Negociaciones con una Empresa de Dispositivos Médicos para Establecer una Presencia en NeoCity

Condado de Osceola, Florida – La Junta de Comisionados del Condado de Osceola ha aprobado un Memorando de Entendimiento (MOU) con Concept Companies y Empyrean Medical Systems, Inc., una empresa global de tecnología en dispositivos médicos, lo que marca otro paso significativo en el desarrollo de NeoCity como un distrito de innovación tecnológico de primer nivel.

Según el MOU aprobado el lunes, Empyrean consideraría alquilar espacio en NeoCity en 2025, con enfoque en ingeniería avanzada y fabricación de piezas de precisión para dispositivos de radiooncología, imágenes médicas y tecnologías superconductoras para sus aceleradores de partículas. La asociación estratégica podría representar la primera fase de un plan integral para establecer una instalación de entre 50,000 y 100,000 pies cuadrados para principios de 2028, que consolidará las operaciones de investigación y desarrollo, fabricación y administración de Empyrean en superconductores y magnetismo avanzado.

“El MOU con Empyrean ejemplifica el tipo de empresas innovadoras y orientadas a la tecnología que estamos atrayendo a NeoCity”, dijo Viviana Janer, Presidenta de la Comisión del Condado de Osceola. “Al aprovechar nuestro ecosistema de semiconductores y nuestra infraestructura técnica avanzada, estamos creando un imán para empresas tecnológicas de vanguardia que impulsan la diversificación económica y la creación de empleos de alto valor”.

La empresa crearía al menos 60 puestos de trabajo altamente calificados con un salario anual promedio de $80,000 para 2033, lo que fortalecería aún más la fuerza laboral de tecnología avanzada de la región.

Empyrean fue fundada para transformar y reemplazar los dispositivos y tecnologías actuales utilizados para tratar a pacientes con cáncer en todo el mundo.

Kal Fishman, Presidente y CEO de Empyrean, comentó: “El sofisticado ecosistema tecnológico de NeoCity nos brinda un entorno incomparable para la innovación. NeoCity nos permite aprovechar una rica red de recursos tecnológicos y talento. De manera única, facilita nuestro trabajo de investigación y desarrollo, fabricación de precisión y producción de nuestros productos y componentes de última generación. Estamos orgullosos de considerar establecer nuestra instalación más avanzada en NeoCity, en nuestro estado natal de Florida, y crear nuevas oportunidades de empleo altamente calificado en el Condado de Osceola, en plena colaboración con Magnetics Corporation, nuestro socio estratégico en este proyecto”.

Magnetics Corporation (MagCorp) es un socio clave que conecta a Empyrean y al Condado, para generar avances continuos hacia un futuro que impulsará generacionalmente tecnologías comerciales críticas en energía y salud.

Concept Companies es el desarrollador inmobiliario para el proyecto y completaría la instalación diseñada específicamente para la empresa en NeoCity, la cual podría tener un tamaño de entre 50,000 y 100,000 pies cuadrados.

“Concept se especializa en proyectos de desarrollo inmobiliario en ciencia, tecnología y atención médica,” dijo Seth Lane, Vicepresidente Ejecutivo de Bienes Raíces de Concept Companies. “Trabajar con Empyrean, con el sólido apoyo del Condado de Osceola y el equipo de NeoCity, dará como resultado un proyecto extraordinario que será transformador para nuestra comunidad.”

Con la aprobación del MOU, el Condado, Concept y Empyrean tienen 120 días para finalizar un acuerdo de desarrollo integral, continuando la visión estratégica del Condado de Osceola de crear un paisaje económico dinámico y orientado a la tecnología.

La inversión se suma al creciente impulso de NeoCity en el desarrollo tecnológico, incluyendo:

Creación del Motor de Innovación de Semiconductores de Florida Central a través de una subvención de la Fundación Nacional de Ciencias.
Fondos críticos del Departamento de Defensa y la Administración de Desarrollo Económico de EE. UU.
Establecimiento de un programa acelerador de semiconductores por Plug and Play.
Alianzas con instituciones tecnológicas líderes como SkyWater Technology, imec USA y varias universidades.

Al atraer empresas innovadoras como Empyrean y construir un ecosistema tecnológico robusto con socios como Concept y MagCorp, el Condado de Osceola se está posicionando a la vanguardia de la innovación de alta tecnología y el crecimiento económico inclusivo.

Sobre Empyrean

Utilizando magnetismo altamente especializado, fotónica, aceleradores de partículas innovadores y ciencia de materiales avanzada, los productos de Empyrean Medical Systems, Inc. integran lo último en física cuántica, superconductores de alta temperatura (HTS), diamantes sintéticos, biología molecular y aprendizaje automático para ofrecer precisión, eficacia y seguridad de clase mundial en el tratamiento del cáncer.

Sobre Concept

Desde 2004, Concept Companies ha creado ambientes que mejoran, empoderan e inspiran. Concept Companies es una empresa inmobiliaria nacional de servicio completo, con oficinas centrales en Gainesville. Ha construido un equipo de expertos de confianza en varios sectores, incluidos desarrollos de uso mixto, ciencia y tecnología, industrial y oficinas. Concept Companies ha desarrollado más de 300 proyectos, sumando más de 10 millones de pies cuadrados en diversos sectores en los Estados Unidos.

Sobre Magnetics Corporation

MagCorp tiene la misión de iniciar la era industrial de la superconductividad mediante sus esfuerzos continuos en el desarrollo tecnológico conjunto en el sector privado, el desarrollo económico en colaboración público-privada y soluciones de crecimiento corporativo. MagCorp lidera la creación del primer ecosistema comercial de HTS del mundo y lo ancla en el estado de Florida para resolver algunos de los desafíos más importantes de la humanidad.

Sobre el Condado de Osceola y NeoCity

El Condado de Osceola es uno de los condados de más rápido crecimiento en la nación. Es una comunidad dinámica e innovadora centrada en una visión de ser el centro de investigación e innovación en manufactura de una economía regional y, al hacerlo, busca mejorar la calidad de vida de sus residentes mediante un manejo responsable de los recursos, servicios públicos innovadores y la participación comunitaria. Tras los impactos de la pandemia de COVID-19, cuando el desempleo alcanzó el 30 % (el más alto del estado), el Condado de Osceola decidió realizar una inversión a largo plazo para crear un distrito tecnológico de 500 acres conocido como NeoCity, con el fin de diversificar su economía. Trabajando con la Fundación Nacional de Ciencias, el Motor de Innovación de Semiconductores de Florida Central busca ser un líder global en el empaquetado avanzado y especializado de semiconductores con oficinas centrales en Florida.

“We are thrilled and honored to partner with MetOx and MagCorp, which provide us several technological and scientific breakthroughs on some of our core technologies and key components for current and future products,” said Kal Fishman, President and CEO of Empyrean. “After commercially launching the Morpheus system this year, we are entering our next phases of innovation and critical technology development. HTS enables Empyrean to implement its technology and products with a higher level of elegance and sophistication while allowing us to constantly push the envelope on physics, materials science, and engineering. By bringing our scientific, engineering, and business teams together through this strategic partnership, we are better positioned to create breakthrough products that are more precise, more effective, and safer in targeting and treating a broad range of cancer indications. We believe the results of this collaboration could present a paradigm shift in our industry, which will revolutionize how we treat cancer and save lives. For our patients. For good.”

“Empyrean has been working in partnership with MagCorp for some time, and this next step in development has been a shared vision from the beginning”, explained Jeff Whalen, Director of MagCorp. “Our team includes the foremost experts in HTS superconducting magnet technology from the National High Magnetic Field Laboratory in Tallahassee, FL, but the missing link in fully leveraging this technology has been the lack of availability of HTS at scale,” Jeff continued. “We’ve been working with MetOx and they’ve exhibited standout leadership and excellent strategic vision for increasing the supply of HTS in an industry that’s proving to be more critical every day. The MagCorp, MetOx and Empyrean partnership is comprised of incredible people with the disruptive and innovative thinking abilities the world needs to solve major challenges like developing game-changing cancer treatment technologies.”

“MetOx has proven its ability to scale its technology and is ready to support the development of novel approaches to medical diagnostics and treatment,” said CEO, Arthur (Bud) Vos. “Only HTS can enable the high magnetic fields required for this exciting technology, and we’re thrilled to partner with Empyrean and MagCorp on this life-saving initiative.”

About Empyrean, MagCorp and MetOx

Empyrean was founded to fundamentally change the way cancer patients are being treated when faced with such a life- altering experience. We take cancer on all its forms personally and with utmost vengeance. We live and work every single day to make a real difference for our patients, their families, and our clinicians all around the world. We will never cease innovating, developing, and launching ground-breaking disruptive technologies to the market until cancer is completely abolished from this world. For more information, visit empyreanmed.com

Empyrean Therapeutics Acquires TLR-2 Antagonist Molecule From Eos Therapies to Advance and Commercialize Breakthrough Cancer Treatment

sageadmin — Mon, 25 Nov 2024 14:49:00 +0000

Online, November 25, 2024 (Newswire.com) – Empyrean Therapeutics, Inc., a pioneering biopharmaceutical company, today announced the successful acquisition of a first-in-class novel TLR-2 antagonist molecule from Eos Therapies, Inc. This strategic move aims to accelerate the development of a new, safe, and effective cancer drug targeting brain, pancreatic, breast, and other hard-to-treat cancers. Designated EMS-312, it is currently in the pre-investigational new drug (pre-IND) phase and is being readied for comprehensive in vivo validation. Empyrean Therapeutics plans to leverage its robust research and development infrastructure and global luminary network to expedite the molecule’s progression toward in-human clinical trials and market launch.

“This acquisition marks a significant milestone for Empyrean Therapeutics,” said Kal Fishman, CEO of Empyrean Therapeutics. “Our EMS-312 small molecule exhibits excellent target affinity, potency, drug-like properties, oral bioavailability, brain uptake, efflux pump avoidance, and it satisfies lead criteria. We are thrilled to integrate it into our pipeline and are committed to advancing it swiftly through the development phases. Our goal is to offer new hope to patients worldwide who are battling some of the most aggressive forms of cancer.”

Doug Bonhaus, PhD, CEO of Eos Therapies, said: “We are very pleased to have completed this transaction with Empyrean Therapeutics, and we look forward to seeing this promising therapeutic candidate advance as a potential first-in-class new treatment for cancer.”

Eos Therapies and Empyrean Therapeutics completed the transaction in October 2024. The EMS-312 molecule has been recently granted patents in all major global markets. Both companies collaborate closely to seamlessly transition all intellectual property, associated research data, and compound materials to Empyrean Therapeutics’ labs at the Center for Novel Therapeutics in La Jolla, CA.

About Empyrean Therapeutics, Inc.

Empyrean Therapeutics, Inc. is dedicated to transforming the landscape of cancer treatment through the development of groundbreaking therapies. Our mission is to harness the power of innovative science to create life-changing medications for patients facing the toughest cancers. With a focus on precision medicine, we aim to deliver treatments that are not only effective but also tailored to individual patient disease states and genomes.

At Empyrean Therapeutics, we believe that collaboration and cutting-edge research are key to unlocking new possibilities in oncology. Our team of scientists and clinicians is committed to pushing the boundaries of science to discover therapies that offer renewed hope and improved outcomes for patients worldwide.

About Eos Therapies, Inc.

Eos Therapies is a San Diego-based company focused on the discovery and clinical development of small molecule Toll-Like Receptor (TLR) antagonists for the treatment of Parkinson’s disease and other neurodegenerative disorders. Our therapeutic approach targets two specific TLRs (TLR2 & TLR9) known to be key drivers of neuroinflammation found in the brain of patients.

Blocking these TLR drivers is expected to disrupt the pathological re-enforcing cycle of inflammation and neurodegeneration leading to slowing of disease progression and improvement of symptoms. Eos Therapies is currently advancing the TLR2/9 antagonist, Eos-003, through preclinical development.

Contact Information

Ms. Madelyn Seal
Empyrean Therapeutics
info@empyreanmed.com
561.931.2086

Doug Bonhaus PhD
Eos Therapies
info@eostherapies.com
+1 (858) 344-2224

About Empyrean, MagCorp and MetOx

Empyrean, MagCorp, and MetOx Announce Strategic Collaboration Agreement on the Scale-up of Novel Technology for Radiation Therapy and Cancer Treatment

sageadmin — Fri, 25 Aug 2023 14:49:00 +0000

Boca Raton, FL – Empyrean Medical Systems, Inc. (“Empyrean”), MagCorp Inc.
(“MagCorp”), and MetOx Technologies, Inc. (“MetOx”) today announced a strategic collaboration agreement to accelerate the large-scale development of novel technology that will enable commercial production of next generation, state-of-the-art radiation therapy technology for cancer treatment.

This trifecta of technology partners brings together MagCorp’s expertise in superconducting magnet technology development using MetOx’s next generation High-Temperature Superconducting wire (HTS) to design and build state-of-the-art radiation therapy technology for Empyrean at a commercial scale.

Empyrean’s robotically-assisted Morpheus beam sculpting image-guided radiotherapy system, taken from concept to FDA submission and clearance in approximately eighteen months, is readying for large-scale production. The success of this manufacturing collaboration will have a dramatic impact on the future of oncology and will unlock the potential of this technology to serve the rapidly growing global need for novel cancer treatment technology.